| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 48 | 2016 | 172 | 2.680 |
Why?
|
| Technetium | 44 | 2016 | 68 | 2.650 |
Why?
|
| Organotechnetium Compounds | 22 | 2013 | 28 | 1.950 |
Why?
|
| Morpholinos | 28 | 2016 | 50 | 1.780 |
Why?
|
| Morpholines | 26 | 2011 | 85 | 1.690 |
Why?
|
| Peptides | 11 | 2013 | 545 | 1.440 |
Why?
|
| Tissue Distribution | 55 | 2022 | 285 | 1.350 |
Why?
|
| Antigens, Neoplasm | 7 | 2013 | 135 | 1.330 |
Why?
|
| Glycoproteins | 6 | 2013 | 194 | 1.260 |
Why?
|
| Biotin | 15 | 2011 | 52 | 1.100 |
Why?
|
| Peptide Library | 5 | 2012 | 35 | 1.090 |
Why?
|
| Indium Radioisotopes | 27 | 2015 | 41 | 1.060 |
Why?
|
| Streptavidin | 16 | 2012 | 32 | 0.960 |
Why?
|
| Isotope Labeling | 33 | 2012 | 68 | 0.940 |
Why?
|
| Mice | 89 | 2022 | 10303 | 0.940 |
Why?
|
| Antibodies | 7 | 2012 | 176 | 0.760 |
Why?
|
| Radionuclide Imaging | 33 | 2008 | 116 | 0.760 |
Why?
|
| Animals | 96 | 2022 | 19718 | 0.750 |
Why?
|
| DNA, Antisense | 11 | 2009 | 17 | 0.730 |
Why?
|
| Neoplasms | 18 | 2022 | 1258 | 0.710 |
Why?
|
| Klebsiella pneumoniae | 3 | 2016 | 26 | 0.710 |
Why?
|
| Colonic Neoplasms | 15 | 2011 | 215 | 0.700 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 11 | 2016 | 191 | 0.700 |
Why?
|
| Oligonucleotides, Antisense | 4 | 2016 | 134 | 0.680 |
Why?
|
| Mice, Nude | 28 | 2015 | 260 | 0.590 |
Why?
|
| Antibodies, Neoplasm | 13 | 2010 | 27 | 0.590 |
Why?
|
| Oligonucleotides | 12 | 2010 | 211 | 0.590 |
Why?
|
| Organometallic Compounds | 6 | 2015 | 64 | 0.570 |
Why?
|
| Cell Line, Tumor | 29 | 2015 | 1378 | 0.570 |
Why?
|
| Klebsiella Infections | 1 | 2016 | 22 | 0.530 |
Why?
|
| Technetium Tc 99m Mertiatide | 7 | 2004 | 7 | 0.530 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 53 | 0.530 |
Why?
|
| Drug Delivery Systems | 15 | 2012 | 310 | 0.510 |
Why?
|
| Neoplasms, Experimental | 9 | 2010 | 74 | 0.490 |
Why?
|
| Bacterial Infections | 3 | 2015 | 138 | 0.480 |
Why?
|
| Fluorescent Dyes | 7 | 2015 | 196 | 0.470 |
Why?
|
| Chelating Agents | 16 | 2012 | 46 | 0.460 |
Why?
|
| Edetic Acid | 5 | 2008 | 21 | 0.440 |
Why?
|
| Diagnostic Imaging | 3 | 2011 | 242 | 0.430 |
Why?
|
| RNA, Bacterial | 1 | 2013 | 70 | 0.430 |
Why?
|
| Positron-Emission Tomography | 8 | 2012 | 174 | 0.420 |
Why?
|
| RNA, Ribosomal, 28S | 1 | 2012 | 3 | 0.420 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 37 | 0.410 |
Why?
|
| Lung Diseases, Fungal | 1 | 2012 | 31 | 0.410 |
Why?
|
| RNA, Fungal | 1 | 2012 | 36 | 0.410 |
Why?
|
| Radioisotopes | 9 | 2010 | 24 | 0.390 |
Why?
|
| Pentetic Acid | 9 | 2010 | 32 | 0.390 |
Why?
|
| Nanoparticles | 9 | 2012 | 499 | 0.390 |
Why?
|
| Biomarkers, Tumor | 6 | 2008 | 460 | 0.380 |
Why?
|
| Escherichia coli Infections | 4 | 2004 | 87 | 0.380 |
Why?
|
| Leukocyte Elastase | 3 | 2001 | 12 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 13 | 2012 | 857 | 0.370 |
Why?
|
| Kidney | 8 | 2013 | 394 | 0.370 |
Why?
|
| Bacteriophages | 2 | 2008 | 48 | 0.350 |
Why?
|
| Bacterial Proteins | 6 | 1997 | 751 | 0.350 |
Why?
|
| Picolinic Acids | 3 | 2015 | 7 | 0.350 |
Why?
|
| Radioimmunodetection | 4 | 2000 | 4 | 0.330 |
Why?
|
| Oligopeptides | 7 | 2006 | 130 | 0.320 |
Why?
|
| Sodium Pertechnetate Tc 99m | 2 | 2008 | 3 | 0.320 |
Why?
|
| Carcinoembryonic Antigen | 10 | 2007 | 33 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 1470 | 0.300 |
Why?
|
| Rhenium | 7 | 2010 | 8 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 19 | 2015 | 197 | 0.290 |
Why?
|
| Microscopy, Fluorescence | 5 | 2016 | 397 | 0.290 |
Why?
|
| Staphylococcal Infections | 4 | 2003 | 115 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2011 | 182 | 0.280 |
Why?
|
| HT29 Cells | 3 | 2011 | 27 | 0.270 |
Why?
|
| Bacteria | 1 | 2008 | 276 | 0.240 |
Why?
|
| Gene Targeting | 5 | 2006 | 82 | 0.240 |
Why?
|
| Fluorescence | 5 | 2011 | 84 | 0.240 |
Why?
|
| Succinimides | 6 | 2002 | 17 | 0.240 |
Why?
|
| Bacteriophage M13 | 1 | 2004 | 2 | 0.230 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 155 | 0.230 |
Why?
|
| Myositis | 1 | 2004 | 5 | 0.230 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 16 | 0.230 |
Why?
|
| Metabolic Clearance Rate | 13 | 2007 | 42 | 0.220 |
Why?
|
| Male | 38 | 2015 | 27765 | 0.220 |
Why?
|
| Neoplasm Transplantation | 10 | 2011 | 159 | 0.220 |
Why?
|
| DNA, Single-Stranded | 4 | 1997 | 100 | 0.210 |
Why?
|
| DNA Probes | 2 | 2009 | 35 | 0.210 |
Why?
|
| Serpins | 2 | 2000 | 17 | 0.210 |
Why?
|
| Bone Morphogenetic Protein Receptors | 2 | 2013 | 14 | 0.210 |
Why?
|
| Smad3 Protein | 2 | 2013 | 18 | 0.210 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 1579 | 0.210 |
Why?
|
| Immunoglobulin G | 9 | 2006 | 452 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 647 | 0.200 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2013 | 64 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2006 | 236 | 0.200 |
Why?
|
| Technetium Compounds | 4 | 2009 | 5 | 0.200 |
Why?
|
| Regeneration | 2 | 2013 | 91 | 0.200 |
Why?
|
| Axonal Transport | 1 | 2022 | 31 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 161 | 0.190 |
Why?
|
| Indicators and Reagents | 3 | 2011 | 43 | 0.190 |
Why?
|
| Base Sequence | 8 | 2013 | 1311 | 0.190 |
Why?
|
| DNA | 6 | 2010 | 793 | 0.190 |
Why?
|
| Humans | 54 | 2022 | 59799 | 0.190 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 1976 | 0.190 |
Why?
|
| Epidermal Growth Factor | 2 | 1998 | 48 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 95 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 2 | 2012 | 177 | 0.170 |
Why?
|
| Species Specificity | 2 | 2012 | 335 | 0.170 |
Why?
|
| Drug Carriers | 4 | 2009 | 175 | 0.170 |
Why?
|
| Vitiligo | 1 | 2022 | 120 | 0.170 |
Why?
|
| Metal Nanoparticles | 1 | 2022 | 180 | 0.170 |
Why?
|
| Biotinylation | 4 | 2012 | 38 | 0.170 |
Why?
|
| Immunoconjugates | 4 | 2010 | 84 | 0.160 |
Why?
|
| Peptide Fragments | 3 | 2008 | 353 | 0.160 |
Why?
|
| Polymers | 4 | 2010 | 317 | 0.160 |
Why?
|
| Mice, Inbred Strains | 10 | 2010 | 182 | 0.160 |
Why?
|
| Endocarditis, Bacterial | 1 | 1999 | 30 | 0.160 |
Why?
|
| Staphylococcus aureus | 2 | 2013 | 159 | 0.150 |
Why?
|
| Kidney Neoplasms | 5 | 2006 | 114 | 0.150 |
Why?
|
| Autoradiography | 5 | 2001 | 54 | 0.150 |
Why?
|
| Protein Binding | 6 | 2011 | 1559 | 0.150 |
Why?
|
| Multimodal Imaging | 3 | 2012 | 67 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2012 | 223 | 0.140 |
Why?
|
| Nucleic Acids | 1 | 1997 | 50 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2022 | 477 | 0.140 |
Why?
|
| Flow Cytometry | 4 | 2011 | 638 | 0.130 |
Why?
|
| Osteomyelitis | 1 | 1996 | 22 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 4 | 2012 | 880 | 0.130 |
Why?
|
| Escherichia coli | 2 | 2013 | 688 | 0.130 |
Why?
|
| Streptococcus pyogenes | 2 | 2015 | 27 | 0.130 |
Why?
|
| Glycine | 3 | 2003 | 45 | 0.130 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 82 | 0.130 |
Why?
|
| Breast Neoplasms | 6 | 2010 | 1128 | 0.130 |
Why?
|
| Yttrium Radioisotopes | 2 | 2013 | 7 | 0.120 |
Why?
|
| Molecular Imaging | 1 | 2015 | 47 | 0.120 |
Why?
|
| Gene Products, tat | 2 | 2006 | 14 | 0.120 |
Why?
|
| Skin | 2 | 2022 | 356 | 0.120 |
Why?
|
| Thymus Gland | 1 | 2015 | 222 | 0.120 |
Why?
|
| Half-Life | 2 | 2013 | 70 | 0.120 |
Why?
|
| Cell Death | 1 | 2015 | 272 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 2079 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 6 | 2009 | 104 | 0.110 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 51 | 0.110 |
Why?
|
| Carbocyanines | 3 | 2010 | 29 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2011 | 1097 | 0.110 |
Why?
|
| Blood Proteins | 5 | 2003 | 72 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 77 | 0.110 |
Why?
|
| Cysteine | 5 | 1997 | 109 | 0.100 |
Why?
|
| Rats | 5 | 2015 | 1918 | 0.100 |
Why?
|
| Oligonucleotide Probes | 1 | 2012 | 43 | 0.100 |
Why?
|
| Spores, Fungal | 1 | 2012 | 15 | 0.100 |
Why?
|
| Nicotinic Acids | 2 | 2003 | 2 | 0.100 |
Why?
|
| Hydrazines | 2 | 2003 | 10 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Avidin | 3 | 2010 | 11 | 0.100 |
Why?
|
| Benzothiazoles | 2 | 2009 | 18 | 0.100 |
Why?
|
| Quinolines | 2 | 2009 | 38 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 483 | 0.100 |
Why?
|
| Organ Specificity | 7 | 2007 | 180 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 12 | 0.100 |
Why?
|
| Injections, Intravenous | 4 | 2013 | 148 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2011 | 22 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 77 | 0.100 |
Why?
|
| Radioimmunotherapy | 2 | 2009 | 7 | 0.090 |
Why?
|
| Trastuzumab | 4 | 2012 | 11 | 0.090 |
Why?
|
| Intestinal Mucosa | 2 | 2013 | 221 | 0.090 |
Why?
|
| Pharmacokinetics | 1 | 2011 | 7 | 0.090 |
Why?
|
| Glucaric Acid | 1 | 2011 | 2 | 0.090 |
Why?
|
| Physics | 1 | 2011 | 12 | 0.090 |
Why?
|
| Luminescence | 1 | 2011 | 19 | 0.090 |
Why?
|
| Phosphorus Compounds | 1 | 2010 | 2 | 0.090 |
Why?
|
| Chemical Fractionation | 1 | 2010 | 13 | 0.090 |
Why?
|
| Amines | 1 | 2010 | 30 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2000 | 183 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Lung | 2 | 2012 | 838 | 0.090 |
Why?
|
| Thionucleotides | 3 | 2001 | 38 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 80 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 52 | 0.090 |
Why?
|
| Liver | 5 | 2010 | 788 | 0.090 |
Why?
|
| Inflammation | 4 | 2012 | 1106 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2001 | 248 | 0.080 |
Why?
|
| Chromatography, Gel | 4 | 2010 | 65 | 0.080 |
Why?
|
| Surface Plasmon Resonance | 2 | 2007 | 33 | 0.080 |
Why?
|
| Consensus Sequence | 1 | 2008 | 28 | 0.080 |
Why?
|
| Polyamines | 1 | 2008 | 11 | 0.080 |
Why?
|
| Forelimb | 1 | 2008 | 8 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2004 | 27 | 0.080 |
Why?
|
| Horse Diseases | 1 | 2008 | 19 | 0.080 |
Why?
|
| Cattle | 2 | 2000 | 306 | 0.080 |
Why?
|
| DNA Primers | 1 | 2008 | 291 | 0.070 |
Why?
|
| Salmonella enterica | 1 | 2008 | 26 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 324 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2008 | 98 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 5 | 2011 | 454 | 0.070 |
Why?
|
| Hydrazones | 1 | 2007 | 4 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2008 | 596 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 638 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2007 | 32 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2015 | 179 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 22 | 0.070 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2006 | 14 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2010 | 603 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 856 | 0.070 |
Why?
|
| Niacinamide | 2 | 1996 | 32 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2008 | 238 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 405 | 0.060 |
Why?
|
| Drug Stability | 6 | 2004 | 138 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1997 | 243 | 0.060 |
Why?
|
| Algorithms | 2 | 2008 | 995 | 0.060 |
Why?
|
| Female | 15 | 2015 | 31093 | 0.060 |
Why?
|
| Aminobutyrates | 1 | 2004 | 10 | 0.060 |
Why?
|
| Ligands | 2 | 2022 | 421 | 0.060 |
Why?
|
| Peptide Nucleic Acids | 2 | 2001 | 17 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 320 | 0.060 |
Why?
|
| Sulfur Radioisotopes | 2 | 2001 | 12 | 0.060 |
Why?
|
| Cell Line | 3 | 2012 | 2015 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 89 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2002 | 427 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2002 | 189 | 0.050 |
Why?
|
| Cytosine | 1 | 2002 | 30 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 75 | 0.050 |
Why?
|
| Whole Body Imaging | 2 | 2015 | 10 | 0.050 |
Why?
|
| Integrins | 1 | 2003 | 106 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 798 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2022 | 14 | 0.050 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2002 | 14 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2022 | 63 | 0.050 |
Why?
|
| Profilins | 1 | 2022 | 45 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 171 | 0.050 |
Why?
|
| Nitriles | 1 | 2002 | 57 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2013 | 125 | 0.050 |
Why?
|
| Culture Techniques | 2 | 2001 | 12 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1141 | 0.050 |
Why?
|
| RNA, Antisense | 1 | 2001 | 49 | 0.050 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 2 | 2012 | 6 | 0.050 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2022 | 136 | 0.050 |
Why?
|
| Liposomes | 1 | 2001 | 100 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 51 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2022 | 197 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2000 | 71 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2022 | 214 | 0.040 |
Why?
|
| Gold | 1 | 2022 | 227 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2012 | 571 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 273 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 1997 | 100 | 0.040 |
Why?
|
| Contrast Media | 1 | 2022 | 414 | 0.040 |
Why?
|
| Phantoms, Imaging | 2 | 2011 | 212 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1992 | 35 | 0.040 |
Why?
|
| Reference Values | 2 | 2002 | 321 | 0.040 |
Why?
|
| Gamma Cameras | 1 | 1999 | 6 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2015 | 492 | 0.040 |
Why?
|
| Intracellular Space | 2 | 2009 | 32 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 1996 | 113 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2006 | 2100 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2012 | 1470 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 1225 | 0.040 |
Why?
|
| Aprotinin | 1 | 1998 | 12 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1998 | 11 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 1998 | 16 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 1991 | 259 | 0.040 |
Why?
|
| Cell Survival | 2 | 2010 | 557 | 0.040 |
Why?
|
| Methods | 1 | 1997 | 38 | 0.040 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1997 | 20 | 0.040 |
Why?
|
| Microspheres | 2 | 2007 | 55 | 0.030 |
Why?
|
| Myocardium | 1 | 1999 | 263 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1203 | 0.030 |
Why?
|
| Indium | 2 | 1987 | 7 | 0.030 |
Why?
|
| Drug Design | 1 | 1997 | 144 | 0.030 |
Why?
|
| Heart | 1 | 1999 | 276 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2012 | 376 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 298 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2015 | 14 | 0.030 |
Why?
|
| Atrophy | 1 | 2015 | 68 | 0.030 |
Why?
|
| Europium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cricetulus | 1 | 2015 | 102 | 0.030 |
Why?
|
| Biological Transport | 2 | 2009 | 288 | 0.030 |
Why?
|
| CHO Cells | 1 | 2015 | 190 | 0.030 |
Why?
|
| Metallothionein | 1 | 1995 | 8 | 0.030 |
Why?
|
| Extremities | 1 | 2015 | 50 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2015 | 68 | 0.030 |
Why?
|
| Dithionite | 1 | 1994 | 2 | 0.030 |
Why?
|
| Kinetics | 4 | 2007 | 737 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 32 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 1994 | 48 | 0.030 |
Why?
|
| Injections | 1 | 2013 | 79 | 0.030 |
Why?
|
| Oxidation-Reduction | 3 | 2004 | 305 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 113 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 742 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 45 | 0.030 |
Why?
|
| Immunoglobulin Fragments | 1 | 1993 | 8 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1996 | 741 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 36 | 0.030 |
Why?
|
| Adsorption | 1 | 2013 | 84 | 0.030 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2012 | 4 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2012 | 35 | 0.030 |
Why?
|
| Lysine | 1 | 1992 | 75 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2003 | 96 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2012 | 5 | 0.020 |
Why?
|
| Captopril | 1 | 2012 | 8 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 5 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2012 | 18 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2013 | 127 | 0.020 |
Why?
|
| Biological Availability | 1 | 2013 | 192 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1992 | 34 | 0.020 |
Why?
|
| Interferons | 1 | 2012 | 63 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 35 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 60 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2004 | 523 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 151 | 0.020 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 2001 | 9 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 142 | 0.020 |
Why?
|
| Animal Structures | 1 | 2010 | 3 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2010 | 12 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 675 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2010 | 1 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 16 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 223 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 54 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 506 | 0.020 |
Why?
|
| Carcinoma | 1 | 1990 | 117 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2009 | 49 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 677 | 0.020 |
Why?
|
| Abdomen | 1 | 2010 | 90 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 511 | 0.020 |
Why?
|
| Models, Structural | 1 | 2009 | 25 | 0.020 |
Why?
|
| Aged | 6 | 1996 | 13461 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 486 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 1996 | 5147 | 0.020 |
Why?
|
| Biological Assay | 1 | 2009 | 54 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 578 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 645 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 195 | 0.020 |
Why?
|
| Dendrimers | 1 | 2008 | 11 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2009 | 128 | 0.020 |
Why?
|
| Adult | 6 | 1996 | 15879 | 0.020 |
Why?
|
| Middle Aged | 6 | 1996 | 16397 | 0.020 |
Why?
|
| Horses | 1 | 2008 | 49 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2009 | 5204 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 125 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 2007 | 18 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 472 | 0.020 |
Why?
|
| Organophosphates | 1 | 2007 | 16 | 0.020 |
Why?
|
| Acids | 1 | 2007 | 14 | 0.020 |
Why?
|
| Phosphates | 1 | 2007 | 90 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1997 | 293 | 0.020 |
Why?
|
| Time Factors | 2 | 2009 | 3589 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2006 | 133 | 0.020 |
Why?
|
| Sugar Acids | 2 | 1996 | 7 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 178 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1985 | 4 | 0.020 |
Why?
|
| Diffusion | 1 | 1985 | 84 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1985 | 99 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1990 | 556 | 0.010 |
Why?
|
| Mercaptoethanol | 2 | 1996 | 4 | 0.010 |
Why?
|
| Tin | 2 | 1996 | 3 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 458 | 0.010 |
Why?
|
| Colon | 1 | 1985 | 138 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1985 | 98 | 0.010 |
Why?
|
| Citrates | 1 | 2003 | 15 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gallium | 1 | 2003 | 12 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Prodrugs | 1 | 2003 | 32 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 63 | 0.010 |
Why?
|
| Acetonitriles | 1 | 2002 | 2 | 0.010 |
Why?
|
| Conjugation, Genetic | 1 | 2001 | 16 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2002 | 127 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 2890 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 66 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 34 | 0.010 |
Why?
|
| Cations | 1 | 2001 | 63 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 215 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 926 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2001 | 165 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 525 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 163 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 276 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 346 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1559 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 502 | 0.010 |
Why?
|
| Ions | 1 | 1992 | 52 | 0.010 |
Why?
|
| Thigh | 1 | 1991 | 25 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1990 | 135 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1991 | 278 | 0.000 |
Why?
|
| Software | 1 | 1990 | 371 | 0.000 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1985 | 3 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1985 | 49 | 0.000 |
Why?
|
| Transferrin | 1 | 1985 | 67 | 0.000 |
Why?
|